To observe the clinical effect of Compound Congrong Yizhi Capsules combined with oxiracetam in treating Alzheimer's disease.Methods:A total of 148 elderly patients with Alzheimer's disease treated in Beijing Longfu Hospital from January 2018 to September 2021 were randomized into a control group(74 patients) and an observation group(74 patients) according to the random number table method.The control group was treated with oxiracetam capsules，while the observation group with oxiracetam capsules combined with Compound Congrong Yizhi Capsules.Both groups were treated for 3 months.The two groups were compared in terms of the clinical effect，the serum levels of oxidative stress indicators and inflammatory cytokines，severity of disease，cholinergic neurotransmitter level，hemorheological indicators，and Mini-Mental State Examination(MMSE) score.Results:The total response rate of the observation group was higher than that of the control group(P<0.05).The serum levels of superoxide dismutase(SOD)，acetylcholine(Ach)，and cholinesterase(AchE)，MMSE score，clock drawing test score，immediate memory，recall，attention，calculating capacity，place orientation，time orientation，and language elevated after treatment in both groups，and the observation group outperformed the control group(P<0.05).The serum levels of malondialdehyde(MDA)，interleukin-1β(IL-1β)，and nuclear factor-κB(NF-κB)，Dementia Scale(CDR) score，high-shear viscosity of whole blood，low-shear viscosity of whole blood，and erythrocyte aggregation index declined after treatment in the two groups and were lower in the observation group than in the control group(P<0.05).Conclusion:Compound Congrong Yizhi Capsules combined with oxiracetam can alleviate the inflammatory and oxidative stress responses to slow down the progression of the disease，regulate the neurotransmitter level and hemorheology，and improve the cognitive function，demonstrating a definite therapeutic effect on Alzheimer's disease.